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Background: A rare variant in the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) gene has been
reported to be a genetic risk factor for Alzheimer’s disease by two independent groups (Odds ratio between 2.9-4.5).
Given the key role of TREM2 in the effective phagocytosis of apoptotic neuronal cells by microglia, we hypothesized
that dysfunction of TREM2 may play a more generalized role in neurodegeneration. With this in mind we set out to
assess the genetic association of the Alzheimer’s disease-related risk variant in TREM2 (rs75932628, p.R47H) with other
related neurodegenerative disorders.
Results: The study included 609 patients with frontotemporal dementia, 765 with amyotrophic lateral sclerosis,
1493 with Parkinson’s disease, 772 with progressive supranuclear palsy, 448 with ischemic stroke and 1957 controls
subjects free of neurodegenerative disease. A significant association was observed for the TREM2 p.R47H substitution
in susceptibility to frontotemporal dementia (OR = 5.06; p-value = 0.001) and Parkinson’s disease (OR = 2.67;
p-value = 0.026), while no evidence of association with risk of amyotrophic lateral sclerosis, progressive
supranuclear palsy or ischemic stroke was observed.
Conclusions: Our results suggest that the TREM2 p.R47H substitution is a risk factor for frontotemporal dementia
and Parkinson’s disease in addition to Alzheimer’s disease. These findings suggest a more general role for TREM2
dysfunction in neurodegeneration, which could be related to its role in the immune response.
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The Triggering Receptor Expressed on Myeloid cells 2
(TREM2) protein is a member of the innate immune re-
ceptor of the TREM family. It is expressed on activated
macrophages, immature dendritic cells, osteoclasts and
microglia [1]. Recent findings support a model in which
TREM2 suppresses inflammation while at the same time* Correspondence: rademakers.rosa@mayo.edu
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reproduction in any medium, provided the orpromoting tissue repair through the removal of apop-
totic cells [2]. Homozygous loss of function mutations in
TREM2 cause a rare autosomal recessive disease known
as polycystic lipomembranous osteodysplasia with scleros-
ing leukoencephalopathy (PLOSL), or Nasu-Hakola disease
[3]. While the mechanisms of neurodegeneration in this
disorder are not completely known, it was proposed that
the lack of TREM2 impairs the clearance of apoptotic neu-
rons by microglia, leading to the accumulation of necrotic
debris [4].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mentia, caused by the demyelination of the central ner-
vous system, with polycystic osseous lesions makes it easy
to distinguish PLOSL from more typical forms of sporadic
and familial frontotemporal dementia (FTD). However,
Guerreiro et al. recently performed next-generation DNA
sequencing in patients with behavioral variant FTD (bvFTD)
without bone cysts and identified homozygous mutations
in TREM2 [5]. Another mutation affecting the 5’ consen-
sus donor splice site in intron 1of TREM2 had been previ-
ously implicated in early-onset dementia without bone
cysts in a Lebanese family [6]. Moreover, a third study has
now identified a homozygous TREM2 p.Y198X mutation
in a family with autosomal recessive FTD from Columbia
that co–segregates with disease, suggesting that TREM2
homozygous mutations can cause a more typical FTD
phenotype [7].
The interest in TREM2 as a genetic risk factor for neu-
rodegenerative diseases greatly increased when two recent
studies independently identified a rare missense mutation
(rs75932628, p.R47H) in the TREM2 gene as an important
risk factor for late-onset Alzheimer’s disease (AD). Jonsson
et al. used whole-genome sequencing data obtained from
2261 Icelandic individuals to identify variants likely to
affect protein function. Upon imputation of these variants
into a series of late-onset AD patients and controls using
genome-wide association data, they showed that the
p.R47H variant conferred a significant, three-fold risk
of late-onset AD. The association was replicated across
additional AD-control series from Europe and the US.
As part of an independent study by Guerreiro et al., we
utilized exome and whole-genome sequencing in AD
patients and identified an increased burden of TREM2
variants in patients compared to controls [5]. The vari-
ants clustered in exon 2 of TREM2 with the substitution
p.R47H displaying the strongest association with risk
of late-onset AD (odds ratio; OR ~4.5). Together these
studies unequivocally implicated TREM2 p.R47H in AD
risk; however its role in other neurodegenerative dis-
eases has not yet been studied.
Given the possible function of TREM2 in the neuro-
immune response and the phenotypic heterogeneityTable 1 Association analysis of TREM2 variant c.140G>A (rs75
Disorder (n) Patient, n (%) Con
Controls (1324) 6
FTD (609) 13 (2.1) 6
ALS (765) 5 (0.7) 6
PD (683) 9 (1.3) 6
PSP (722) 5 (0.6) 6
Ischemic Stroke (448) 3 (0.7) 6
a Uncorrected p-values are shown. The association in FTD would remain significant
level p<0.01).observed in carriers of TREM2 mutations, we hypothe-
sized that the TREM2 p.R47H substitution may be a
general risk factor for neurodegenerative disorders. In
the present study, we genotyped this variant in a series
of well-characterized neurodegenerative patients with
amyotrophic lateral sclerosis (ALS), FTD, Parkinson’s dis-
ease (PD), progressive supranuclear palsy (PSP), and ische-
mic stroke as well as a series of healthy controls.
Results
Genotype and allele distributions were in Hardy–Weinberg
equilibrium (HWE) in all cohorts. Table 1 displays the car-
rier frequency, odds ratios (OR), 95% confidence intervals
(CIs), and p-values for each disease cohort in comparison
to the controls series. We observed a carrier frequency of
0.45% (6/1324) in our North American control series which
is similar to the frequency reported in our independent
controls used for our previous study of TREM2 p.R47H
in AD (0.37%; 15/4061) [5]. Using our control series
(n=1324), we identified a significant association with the
rs75932628 (p.R47H) variant in both the North American
FTD series (OR = 5.06; p-value = 0.0012) and the North
American PD series (OR = 3.14; p-value = 0.033). In the
FTD series the association was observed to be stronger in
the clinical series (OR = 5.46; p-value=0.0009) compared
to the pathologic-confirmed cases with frontotemporal
lobar degeneration with TDP-43 pathology (FTLD-TDP,
OR = 3.56, p=0.14); however this could be, at least in part,
related to the smaller autopsy series (n=132). A second
FTD series was unavailable for replication.
In an attempt to replicate the association of p.R47H
with PD we studied two additional patient-control series
of European Caucasian descent from Ireland and Poland.
Although the association analysis was not statistically
significant in these series we did observe an increased
frequency of TREM2 p.R47H in the PD patients from
both populations. Interestingly, the frequency of TREM2
p.R47H was much lower in the Polish population and
was not observed at all in the control subjects (Table 2).
A combined analysis of all three PD patient-control series
further confirmed the significant association of p.R47H
with PD risk (OR = 2.67; p-value= 0.026).932628; p.R47H) in disease
trol, n (%) OR (95% CI) p-valuea
(0.45)
(0.45) 5.064 (1.9, 13.51) 0.0012
(0.45) 1.466 (0.43, 4.94) 0.5378
(0.45) 3.144 (1.1, 9.03) 0.0333
(0.45) 1.537 (0.41, 5.78) 0.5249
(0.45) 1.506 (0.37, 6.17) 0.5689
after a conservative Bonferroni correction for multiple testing (significance
Table 2 Parkinson's disease association analysis of TREM2 variant c.140G>A (rs75932628; p.R47H)
Disorder (n) Patient, n (%) Control, n (%) OR (95% CI) p-valuea
Control (1957) 8 (0.41)
Combined (1493) 16 (1.07) 8 (0.41) 2.670 (1.13, 6.33) 0.0256
North American PD (683) 9 (1.32) 6 (0.45) 3.144 (1.1, 9.03) 0.0333
Irish PD (367) 5 (1.36) 2 (0.54) 2.509 (0.47, 13.41) 0.2821
Polish PD (443) 2 (0.45) 0 NA NA
a Uncorrected p-values are shown.
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North-American ALS series (OR = 1.47; p-value = 0.538),
North-American PSP (OR = 1.54; p-value = 0.525) or
the North-American ischemic stroke series (OR = 1.51;
p-value = 0.569), although an increased frequency of
p.R47H was observed across all diseases.
Discussion
There are a number of pathways that are likely generalized
across the myriad of neurodegenerative disorders, includ-
ing the ubiquitin-proteasome system, mitochondrial dys-
function and the inflammatory response. TREM2 is an
important player in the immune response and loss-of-
function mutations in TREM2 have been demonstrated
to cause a spectrum of dementia-like phenotypes with
or without bone cysts [3,5,7]. The recent identification
of a rare TREM2 substitution (p.R47H) as a risk factor
for AD now suggests that the protein plays an important
role in neurodegeneration [5,8]. To further investigate
TREM2 in disease we examined the frequency of p.R47H
in a number of other disorders and identified a significant
association with disease risk for FTD (OR 5.06) and PD
(OR 2.67). These findings suggest that dysfunction of
TREM2 may be involved in pathways that are underlying
specific neurodegenerative processes, while the lack of as-
sociation for PSP and ALS argues against a generalized
immune dysfunction.
There is growing evidence to support the role of acti-
vated microglia pathways in neurodegeneration. A recent
integrated systems approach by Zhang and colleagues
examining genotype and whole-genome expression pro-
files of tissue from 1,647 late-onset AD and controls iden-
tified DAP12 (TYROBP) as one of the key genes with
differential expression in disease [9]. The authors also
highlight their unpublished studies demonstrating that
DAP12 is involved in amyloid-beta turnover and neuronal
damage. TREM2 is a transmembrane signaling receptor
expressed by microglial cells and functions with DAP12 to
effect downstream signaling via β-catenin [10]. Recessive
mutations in both TREM2 and DAP12 produce the
clinical phenotype of Nasu-Hakola disease [3,11]. Inter-
estingly, our group recently described mutations in the
colony-stimulating factor receptor gene (CSF1R) in heredi-
tary diffuse leukoencephalopathy with spheroids (HDLS)[12]. CSF1R is another member of this immune-related
pathway and is a crucial mediator of microglial prolifera-
tion and differentiation in the brain. CSF1R also signals
through β-catenin after stimulation by CSF1 [10]. HDLS
can clinically manifest with personality and behavioral
changes, dementia, parkinsonism, and related conditions,
but not ALS, PSP or typical ischemic stroke. The reason
for the selective presentation of HDLS patients with this
set of clinical symptoms is currently unclear but may be
dependent on specific downstream signaling pathways
that are affected. If the p.R47H mutation in TREM2 af-
fects the same pathway, this could provide a possible
explanation for our lack of association with ALS, PSP
and ischemic stroke.
This is the first report of an association of TREM2
p.R47H with neurodegenerative diseases other than AD
and it is therefore important to consider potential con-
founding factors. While it is expected that in our clinical
FTD series a subset of patients may in fact have a different
pathological diagnosis, including AD [13,14], we observed a
stronger odds ratio in our FTD series compared to previous
reports in AD. Moreover, the association was strongest in
our clinical series. The fact that multiple FTD families with
recessive mutations in TREM2 were also recently reported
further strengthens a significant role for TREM2 in FTD.
However, whether the concomitant amyloid pathology
which is likely to exist in a substantial fraction of clinically
diagnosed PD patients in our series could potentially con-
tribute to the association of TREM2 p.R47H with PD is a
question that we cannot address with our current study.
Association studies in pathologically defined Lewy-body
disease cohorts with and without amyloid pathology may
be able to address this in future studies.
For years, research in these complex neurodegenera-
tive diseases has focused on the study of common vari-
ants through genome-wide association studies; however,
it is clear that common variants do not explain all the
heritability described for these disorders. On the other
hand, rare population variants with large or intermediate
risk effect sizes have been more difficult to determine.
As genetic technologies have now become more advanced
the identification of intermediate risk variants such as
p.R47H in TREM2 will also increase. The elucidation of
these factors is extremely important and will provide
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generate novel in vitro and in vivo systems in which to
model the disease and screen therapeutics.
Conclusions
Our study provides strong support for a role of the
p.R47H variant in TREM2 in the etiology of FTD and PD.
Together with the previous work implicating p.R47H in
AD; these new findings suggest that the TREM2 p.R47H
variant likely confers risk by altering the function of
microglia, potentially by becoming less effective in the
suppression of inflammation and clearance of apoptotic
debris. Future work focused on the impact of p.R47H
on TREM2 function is needed to clarify its precise role
in these complex neurodegenerative disorders.
Materials and methods
Subjects
Demographics for the individual study groups are given
in Table 3. All patients and controls were of Caucasian
ancestry. Our ALS cohort (n = 765) consisted of 474
clinically diagnosed patients obtained from the Coriell
Institute for Medical Research, 260 unrelated patients
diagnosed with ALS according to El Escorial criteria from
a consecutive clinical case series seen at the Mayo Clinic
Jacksonville (MCJ) ALS Center, 3 patients from the
University of California, San Francisco (UCSF), one pa-
tient from Northwestern University Feinberg School of
Medicine.
An additional 27 pathologically confirmed ALS patients
were obtained from the MCJ brain bank. The FTD cohort
(n = 609) included 477 clinically diagnosed FTD patients
of unknown pathological subtype diagnosed with bvFTD,
semantic dementia (SD) or progressive non-fluent aphasia
(PNFA) and 132 patients with pathologically confirmed
FTLD-TDP. The diagnoses of bvFTD, SD and PNFA wereTable 3 Demographic data of patients and controls
included in the study
Series n Age (years) Females (%)
Controls 1957 63.6 ± 15.7 54.6
North American 1324 64.0 ± 13.1 54.5
Irish 370 66.0 ± 22.2 63.2
Polish 263 59.5 ± 15.5 47.5
Amyotrophic lateral sclerosis 765 59.5 ± 12.1 42.5
Frontotemporal dementia 609 66.6 ± 10.3 47.5
Progressive supranuclear palsy 772 74.8 ± 7.7 43.3
Ischemic Stroke 448 66.0 ± 14.6 40.8
Parkinson's Disease 1493 59.7 ± 12.4 39.6
North American 683 63.8 ± 11.6 36.5
Irish 367 55.8 ± 12.1 44.7
Polish 443 56.4 ± 11.8 36.8made using the Neary criteria [15]. FTD patients were
ascertained from a total of 9 Centers between 1995 and
2010, including MCJ (n=179).
Mayo Clinic Rochester (n=134), Mayo Clinic Scottsdale
(n=9), UCSF (n=117), Northwestern University Feinberg
School of Medicine (n=21), Drexel University College of
Medicine (n=24).
University of Texas Southwestern Medical Center (n=6),
University of British Columbia, Canada (n=12), University
of Western Ontario, Canada (n=42), and the MCJ brain
bank (n=65). Importantly all ALS and FTD patients were
previously analyzed for the C9ORF72 repeat expansion,
whereas FTD patients were also screened for mutations
in the microtubule associated protein tau (MAPT) and
progranulin (GRN) and all mutation carriers were ex-
cluded. PD patients (n = 683) were ascertained at MCJ
and clinically diagnosed with PD according to published
criteria [16]. The PD replication cohort consisted of 367
clinical cases and 370 controls from Ireland, and 443
clinical patients and 263 controls from Poland. All PD
patients were screened for Leucine-Rich Repeat Kinase
2 (LRRK2) G2019S and all mutation carriers were ex-
cluded. The PSP series was made up of 772 subjects
from the MCJ brain bank with pathologically confirmed
PSP. Our Ischemic stroke cohort contains 448 patients
from the Ischemic Stroke Genetics Study [17]. Finally, a
cohort of unrelated US Caucasian control individuals
free of neurodegenerative diseases (n = 1324), with no
overlap to our earlier reported TREM2 control population,
was also available for genetic association studies. The eth-
ics review board at Mayo Clinic approved the study.
Genotyping
Genomic DNA was extracted from peripheral blood lym-
phocytes or brain tissue using standard procedures. The
TREM2 variant in exon 2 c.140G>A (rs75932628; p.R47H)
was genotyped using a TaqMan Allelic Discrimination
Assay on an ABI 7900HT Fast Real-Time PCR system
(Applied Biosystems, Foster City, CA, USA). Positive con-
trols were included to confirm assays were optimized for
both alleles. Data analysis was performed using SDS 2.2.2
software. Positive or ambiguous results in the TaqMan
assay were also confirmed and resolved via Sanger se-
quencing [18].
Statistical analysis
The association between the TREM2 variant rs75932628
(p.R47H) and each neurodegenerative disease was evalu-
ated using a logistic regression model adjusted for age
(age at final diagnosis for patients and age at blood draw
for controls) and gender, where odds ratios (ORs) and
95% confidence intervals (CIs) were estimated. Given the
low minor allele frequency and lack of homozygosity we
examined association for TREM2 p.R47H and disease
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statistically significant and analyses were performed using
PLINK (http://pngu.mgh.harvard.edu/purcell/plink/) [19].
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